Sotera Health’s (SHC) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

Posted by Francis Steltz on Oct 14th, 2026

Sotera Health (NASDAQ:SHC – Get Free Report)‘s stock had its “underweight” rating reissued by analysts at JPMorgan Chase & Co. in a report issued on Wednesday, Benzinga reports. They presently have a $17.00 target price on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 6.64% from the stock’s previous close.

SHC has been the topic of several other research reports. Wall Street Zen raised shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 29th. Citigroup raised their price objective on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings raised shares of Sotera Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective on shares of Sotera Health in a research note on Tuesday, September 8th. Finally, UBS Group set a $19.00 target price on shares of Sotera Health in a report on Wednesday, June 24th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.38.

Read Our Latest Research Report on Sotera Health

Sotera Health Trading Up 0.3%

Shares of SHC opened at $18.21 on Wednesday. The business has a 50-day moving average of $18.71 and a 200 day moving average of $17.10. Sotera Health has a fifty-two week low of $13.09 and a fifty-two week high of $19.85. The firm has a market cap of $5.20 billion, a P/E ratio of 21.35 and a beta of 1.85. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80.

Sotera Health (NASDAQ:SHC – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. The business had revenue of $321.38 million for the quarter, compared to analysts’ expectations of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. As a group, research analysts forecast that Sotera Health will post 0.87 EPS for the current year.

Insider Activity at Sotera Health

In other Sotera Health news, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the sale, the chairman directly owned 3,969,393 shares in the company, valued at $73,433,770.50. This represents a 17.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael P. Rutz sold 150,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the completion of the transaction, the insider directly owned 334,279 shares of the company’s stock, valued at approximately $6,297,816.36. The trade was a 30.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,294,515 shares of company stock worth $23,999,528 over the last quarter. Corporate insiders own 15.36% of the company’s stock.

Institutional Investors Weigh In On Sotera Health

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC boosted its stake in Sotera Health by 217.5% during the first quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after buying an additional 1,455 shares during the period. Meeder Asset Management Inc. bought a new position in Sotera Health in the 2nd quarter worth about $37,000. Nykredit A S bought a new position in Sotera Health in the 2nd quarter worth about $50,000. IFP Advisors Inc increased its stake in Sotera Health by 150.8% in the 2nd quarter. IFP Advisors Inc now owns 3,509 shares of the company’s stock worth $62,000 after acquiring an additional 2,110 shares during the last quarter. Finally, Strs Ohio increased its stake in Sotera Health by 20.1% in the 1st quarter. Strs Ohio now owns 5,881 shares of the company’s stock worth $84,000 after acquiring an additional 986 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

(Get Free Report)

Sotera Health Company (NASDAQ:SHC) is a global provider of healthcare services focused on sterilization, laboratory testing and infection prevention. The company serves medical device manufacturers, pharmaceutical companies, biotechnology businesses, hospitals and other healthcare organizations.

Sotera Health operates through three primary businesses. Sterigenics provides outsourced sterilization and medical device services using technologies such as ethylene oxide, gamma irradiation and electron beam processing.